Clinical trial NCT02790645: Telemedicine Program in Type 1 Diabetes and CSII
Official title: Randomized Crossover Clinical Trial in Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion to Assess the Impact of Telemedicine vs. Conventional Medical Care. Integral Clinical Impact and Cost
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Keywords: Type 1 diabetes
Health technologies
Continuous subcutaneous insulin infusion
Telemedicine
Glycemic variability
Inflammatory markers,
Oxidative stress
Depression
Quality of life
Cost-effectiveness
Lead sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Sponsor class: OTHER
Collaborators: name: Ministerio de Economía y Competitividad, Spain
name: Andaluz Health Service
name: Roche Pharma AG
First posted: 2016-06-06
Enrollment: 51
Sex: ALL
Minimum age (years): 16
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Diabetes mellitus is a chronic disease of high socio-health relevance for their clinical and economic implications (risk of complications, disability ...) (healthcare costs). Strict glycemic control and intensive treatment and support have shown long-term patient with type 1 diabetes mellitus (DM1) improved health. The intensive insulin therapy involves the administration of insulin through 3 or more injections per day (MDI), or through a continuous subcutaneous insulin infusion (CSII). New technologies applied to the treatment of DM1, such as telemedicine, could bring benefits to patients. The available scientific evidence to date shows that telemedicine systems have beneficial or neutral effects on glycemic control, expressed in terms of HbA1c in patients with type 1 diabetes treated with MDI or CSII. They have also shown not to worsen the quality of life and reduce the costs associated with the care of these subjects. However, studies published to date are generally short follow-up, small sample size, and have not evaluated other biological parameters such as glycemic variability, inflammatory markers and markers of oxidative stress as well as a psychological assessment including depression, anxiety, Diabetes-related distress and fear of hypoglycemia. It has been designed a randomized crossover 18 months in order to study the effect of a telemedicine program in a group of subjects with DM1 in CSII on clinical variables of metabolic control variables, including parameters of glycemic variability, markers of inflammation and oxidative stress, psychological variables and quality of life, and associated costs.

Detailed description: Randomized crossover clinical trial about the impact of a telemedicine program (Emminens Conecta® System, Roche Diagnostics SL) vs. the conventional medical follow-face of 18 months for the care of patients with DM1 intensive treatment with CSII (Accu-Chek Spirit®, Roche SL).

Two groups: one group with interactive clinical monitoring through a telemedicine platform (TM) and other conventional medical follow-up group (SMC) during 6 months. Being a crossover trial, both groups passing through both conditions (TM and SMC) during 6 months.

Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes over 2 years of development with C plasma levels \<0.5 ng / ml, and ISCI treated for\> 6 months peptide.
* Age between 16 and 65 years (inclusive).
* HbA1c \<10%.
* Absence of concomitant drug therapy that could affect blood glucose levels.
* Absence of chronic renal failure, abnormal liver function tests, thyroid disease active (except properly replaced hypothyroidism).
* Absence of acute decompensation Ketotic at baseline.

Exclusion Criteria:

* type 2 diabetes.
* type 1 diabetes treated with multiple daily insulin injections.
* Women pregnant or planning pregnancy.
* severe macrovascular or microvascular complications
* disabling psychological disorders.
* No collaboration (not signed informed consent).

Primary outcomes:
measure: Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Secondary outcomes:
measure: Assessment of inflammatory markers (hs-CRP).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of inflammatory markers (IL-6).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of inflammatory markers (TNF-α).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of inflammatory markers (MCP-1).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of inflammatory markers (hs-CRP).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of inflammatory markers (IL-6).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of inflammatory markers (TNF-α).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of inflammatory markers (MCP-1).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of redox markers (CAT).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of redox markers (TBARS).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of redox markers (oxidized LDL).
timeFrame: Baseline: Group 1 and 2
measure: Assessment of redox markers (CAT).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of redox markers (TBARS).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of redox markers (oxidized LDL).
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of quality of life with the DQOL
timeFrame: Baseline: Group 1 and 2
measure: Assessment of quality of life with the DQOL
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of depression with the BDI-II
timeFrame: Baseline: Group 1 and 2
measure: Assessment of depression with the BDI-II
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of anxiety with the STAI
timeFrame: Baseline: Group 1 and 2
measure: Assessment of anxiety with the STAI
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of distress related to diabetes with the DDS
timeFrame: Baseline: Group 1 and 2
measure: Assessment of distress related to diabetes with the DDS
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of treatment satisfaction with the DTSQ
timeFrame: Baseline: Group 1 and 2
measure: Assessment of treatment satisfaction with the DTSQ
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of fear of hypoglycemia with the FH-15
timeFrame: Baseline: Group 1 and 2
measure: Assessment of fear of hypoglycemia with the FH-15
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.
timeFrame: Baseline: Group 1 and 2; 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
measure: Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.
timeFrame: 6 months: Control (Group1a+Group 2b) vs Telemedicine ( Group 2a+ Group1b)
Other outcomes:
Locations:
Study officials:
affiliation: Andaluz Health Service
name: Soledad Ruiz de Adana, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jansa M, Vidal M, Viaplana J, Levy I, Conget I, Gomis R, Esmatjes E. Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control. Diabetes Res Clin Pract. 2006 Oct;74(1):26-32. doi: 10.1016/j.diabres.2006.03.005. Epub 2006 Apr 18.
citation: Blanchet KD. Telehealth and diabetes monitoring. Telemed J E Health. 2008 Oct;14(8):744-6. doi: 10.1089/tmj.2008.8483. No abstract available.